OptiMedica Secures $16 Million in Series C Funding

Business Wire, March 26, 2008

SANTA CLARA, Calif. -- OptiMedica Corp., a global ophthalmic device company, has announced the receipt of $16 million in Series C financing. Participants in the round included the company's existing venture investors, Kleiner, Perkins, Caufield & Byers and Alloy Ventures, as well as new investment partner DAG Ventures. The Series C financing will be used towards the expansion of OptiMedica's commercial presence and the development of its new technology portfolio.

"Our further support of OptiMedica represents our strong, continued belief in the significant advances the company is contributing to the field of ophthalmology for the benefit of patients across the globe," said Brook Byers, partner, Kleiner, Perkins, Caufield & Byers, and chairman of the board, OptiMedica. "We are very optimistic about the company's immediate growth prospects and long-term technology pipeline."

Founded in 2004, OptiMedica has the exclusive worldwide rights to and has commercialized the groundbreaking PASCAL([R]) (PAttern SCAn Laser) Photocoagulator system. Since its market introduction in 2006, PASCAL photocoagulation procedures have been performed on thousands of patients worldwide.

"This Series C financing is an important milestone for OptiMedica, as we continue our aggressive global expansion," said Mark J. Forchette, president and CEO. "Our venture capital partners are simply outstanding, and we are very pleased with the continued confidence they have demonstrated with this series of financing. We are also thrilled to welcome DAG Ventures, another exceptional venture investor, as a significant new part of OptiMedica's rapidly growing team."

About OptiMedica

OptiMedica Corp. is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. OptiMedica holds the exclusive license to the PASCAL([R]) (PAttern SCAn Laser) method of photocoagulation and its associated technologies, which are approved by the U.S. Food and Drug Administration for treatment of a variety of retinal conditions. Clinical experience with PASCAL has demonstrated unmatched precision, efficiency and patient comfort. Founded in 2004, the company is headquartered in Santa Clara, Calif., with international offices in Singapore. OptiMedica is funded by Kleiner Perkins Caufield & Byers, Alloy Ventures and DAG Ventures. For more information, please visit www.optimedica.com.